These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28249876)

  • 1. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies.
    Toth PP; Descamps O; Genest J; Sattar N; Preiss D; Dent R; Djedjos C; Wu Y; Geller M; Uhart M; Somaratne R; Wasserman SM;
    Circulation; 2017 May; 135(19):1819-1831. PubMed ID: 28249876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.
    Stein EA; Giugliano RP; Koren MJ; Raal FJ; Roth EM; Weiss R; Sullivan D; Wasserman SM; Somaratne R; Kim JB; Yang J; Liu T; Albizem M; Scott R; Sabatine MS;
    Eur Heart J; 2014 Sep; 35(33):2249-59. PubMed ID: 24598985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
    O'Donoghue ML; Giugliano RP; Wiviott SD; Atar D; Keech A; Kuder JF; Im K; Murphy SA; Flores-Arredondo JH; López JAG; Elliott-Davey M; Wang B; Monsalvo ML; Abbasi S; Sabatine MS
    Circulation; 2022 Oct; 146(15):1109-1119. PubMed ID: 36031810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia.
    Hovingh GK; Raal FJ; Dent R; Stefanutti C; Descamps O; Masana L; Lira A; Bridges I; Coll B; Sullivan D
    J Clin Lipidol; 2017; 11(6):1448-1457. PubMed ID: 29066265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.
    Koren MJ; Giugliano RP; Raal FJ; Sullivan D; Bolognese M; Langslet G; Civeira F; Somaratne R; Nelson P; Liu T; Scott R; Wasserman SM; Sabatine MS;
    Circulation; 2014 Jan; 129(2):234-43. PubMed ID: 24255061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
    Sabatine MS; Giugliano RP; Wiviott SD; Raal FJ; Blom DJ; Robinson J; Ballantyne CM; Somaratne R; Legg J; Wasserman SM; Scott R; Koren MJ; Stein EA;
    N Engl J Med; 2015 Apr; 372(16):1500-9. PubMed ID: 25773607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus.
    Sattar N; Toth PP; Blom DJ; Koren MJ; Soran H; Uhart M; Elliott M; Cyrille M; Somaratne R; Preiss D
    Am J Cardiol; 2017 Nov; 120(9):1521-1527. PubMed ID: 28844508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT.
    Santos RD; Ruzza A; Hovingh GK; Stefanutti C; Mach F; Descamps OS; Bergeron J; Wang B; Bartuli A; Buonuomo PS; Greber-Platzer S; Luirink I; Bhatia AK; Raal FJ; Kastelein JJP; Wiegman A; Gaudet D
    Lancet Diabetes Endocrinol; 2022 Oct; 10(10):732-740. PubMed ID: 36075246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
    Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis.
    Koren MJ; Roth EM; McKenney JM; Gipe D; Hanotin C; Ferrand AC; Wu R; Dufour R
    Postgrad Med; 2015 Mar; 127(2):125-32. PubMed ID: 25609019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-Year Efficacy and Safety of Evolocumab in Japanese Patients　- A Pooled Analysis From the Open-Label Extension OSLER Studies.
    Hirayama A; Yamashita S; Inomata H; Kassahun H; Cyrille M; Ruzza A; Yoshida M; Kiyosue A; Ma Y; Teramoto T
    Circ J; 2017 Jun; 81(7):1029-1035. PubMed ID: 28367845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study.
    Gaudet D; Langslet G; Gidding SS; Luirink IK; Ruzza A; Kurtz C; Lu C; Somaratne R; Raal FJ; Wiegman A
    J Clin Lipidol; 2018; 12(5):1199-1207. PubMed ID: 30318065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia.
    Koren MJ; Sabatine MS; Giugliano RP; Langslet G; Wiviott SD; Ruzza A; Ma Y; Hamer AW; Wasserman SM; Raal FJ
    J Am Coll Cardiol; 2019 Oct; 74(17):2132-2146. PubMed ID: 31648705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.
    Langley RG; Papp K; Gottlieb AB; Krueger GG; Gordon KB; Williams D; Valdes J; Setze C; Strober B
    J Eur Acad Dermatol Venereol; 2013 Oct; 27(10):1252-61. PubMed ID: 23157612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
    JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
    Blom DJ; Hala T; Bolognese M; Lillestol MJ; Toth PD; Burgess L; Ceska R; Roth E; Koren MJ; Ballantyne CM; Monsalvo ML; Tsirtsonis K; Kim JB; Scott R; Wasserman SM; Stein EA;
    N Engl J Med; 2014 May; 370(19):1809-19. PubMed ID: 24678979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.
    Dias CS; Shaywitz AJ; Wasserman SM; Smith BP; Gao B; Stolman DS; Crispino CP; Smirnakis KV; Emery MG; Colbert A; Gibbs JP; Retter MW; Cooke BP; Uy ST; Matson M; Stein EA
    J Am Coll Cardiol; 2012 Nov; 60(19):1888-98. PubMed ID: 23083772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
    Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolocumab (AMG 145) for primary hypercholesterolemia.
    Langslet G; Emery M; Wasserman SM
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):477-88. PubMed ID: 25824308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
    JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.